Analysts reiterate Buy on Corcept after EMA CHMP support
EMA CHMP backed relacorilant plus nab—paclitaxel for platinum—resistant ovarian cancer; HC Wainwright reiterated Buy and a $165 target, implying ~43.7% upside ahead of an EU decision.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.